Covered recipient · General Payments record
BRYAN J BADIK
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2023
$5,013.22
- Reported across 397 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $309.49 | 18 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $127.86 | 8 |
| ABBVIE INC. | $72.76 | 4 |
| PFIZER INC. | $44.60 | 2 |
| Actelion Pharmaceuticals US, Inc. | $20.04 | 1 |
| Lilly USA, LLC | $16.04 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $15.48 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $12.71 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $16.65 | 03/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996187613 | CMS |
| AbbVie Inc. | $16.90 | 07/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996187615 | CMS |
| AbbVie Inc. | $18.71 | 10/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996187617 | CMS |
| AbbVie Inc. | $20.50 | 11/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996187619 | CMS |
| Actelion Pharmaceuticals US, Inc. | $20.04 | 03/28/2023 | Food and Beverage | Undisputed | 01/23/2026 | 988589703 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $15.48 | 02/01/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000080503 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $12.71 | 05/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1034521661 | CMS |
| Lilly USA, LLC | $16.04 | 02/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1031296457 | CMS |
| Novo Nordisk Inc | $18.90 | 01/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000349495 | CMS |
| Novo Nordisk Inc | $15.45 | 01/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000349481 | CMS |
| Novo Nordisk Inc | $20.29 | 01/27/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000349501 | CMS |
| Novo Nordisk Inc | $14.29 | 02/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000349463 | CMS |
| Novo Nordisk Inc | $15.30 | 02/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000349475 | CMS |
| Novo Nordisk Inc | $13.25 | 02/28/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000349457 | CMS |
| Novo Nordisk Inc | $14.59 | 05/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000349469 | CMS |
| Novo Nordisk Inc | $15.79 | 06/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000349489 | CMS |
| PFIZER INC. | $17.63 | 03/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1049245167 | CMS |
| PFIZER INC. | $26.97 | 07/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050521091 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.